GTx (Pharmaceuticals) Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Employees
-
139
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$26M
GTx (Pharmaceuticals) General Information
Description
GTx Inc is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of small molecules for the treatment of cancer including treatment of breast and prostate cancer and other serious medical conditions such as Stress urinary incontinence and Duchenne muscular dystrophy. Its lead product candidate is Enobosarm. The company's strategy is focused on the further development of selective androgen receptor modulators.
Contact Information
Website
www.gtxinc.comCorporate Office
- 175 Toyota Plaza
- 7th Floor
- Memphis, TN 38103
- United States
Corporate Office
- 175 Toyota Plaza
- 7th Floor
- Memphis, TN 38103
- United States
GTx (Pharmaceuticals) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 07-Jun-2019 | $26M | Completed | Generating Revenue | ||
| 7. Secondary Transaction - Open Market | 26-Sep-2018 | Completed | Generating Revenue | |||
| 6. PIPE | 28-Sep-2017 | Completed | Generating Revenue | |||
| 5. PIPE | 24-Nov-2014 | Completed | Generating Revenue | |||
| 4. Grant | 03-Nov-2010 | Completed | Generating Revenue | |||
| 3. IPO | 03-Feb-2004 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series E) | 20-Aug-2003 | $20M | $20M | Completed | Product Development | |
| 1. Early Stage VC | 13-Oct-2002 | Completed | Startup |
GTx (Pharmaceuticals) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B2 | ||||||||
| Series B | ||||||||
| Series A2 | 140,000 | $0.001000 | $7.28 | $7.28 | 1x | $57.66 | 0.18% | |
| Series A | 200,000 | $0.001000 | 8% | $7.28 | $7.28 | 1x | $7.28 | 2.02% |
GTx (Pharmaceuticals) Comparisons
Industry
Financing
Details
GTx (Pharmaceuticals) Competitors (40)
One of GTx (Pharmaceuticals)’s 40 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Exelixis | Formerly VC-backed | Alameda, CA | ||||
| Kyntra Bio | Formerly VC-backed | San Francisco, CA | ||||
| Monopar Therapeutics | Formerly VC-backed | Wilmette, IL |
GTx (Pharmaceuticals) Signals
GTx (Pharmaceuticals) Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| Amzak Capital Management | Family Office | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| MB Venture Partners | Venture Capital | Minority | ||
| Oracle Investment Management | Hedge Fund | Minority |
GTx (Pharmaceuticals) Acquisitions (1)
GTx (Pharmaceuticals)’s most recent deal was a Reverse Merger with Oncternal Therapeutics. The deal was made on 07-Jun-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oncternal Therapeutics | 07-Jun-2019 | Reverse Merger | Drug Discovery |
GTx (Pharmaceuticals) FAQs
-
When was GTx (Pharmaceuticals) founded?
GTx (Pharmaceuticals) was founded in 1997.
-
Where is GTx (Pharmaceuticals) headquartered?
GTx (Pharmaceuticals) is headquartered in Memphis, TN.
-
What is the size of GTx (Pharmaceuticals)?
GTx (Pharmaceuticals) has 139 total employees.
-
What industry is GTx (Pharmaceuticals) in?
GTx (Pharmaceuticals)’s primary industry is Drug Discovery.
-
Is GTx (Pharmaceuticals) a private or public company?
GTx (Pharmaceuticals) is a Private company.
-
What is the current valuation of GTx (Pharmaceuticals)?
The current valuation of GTx (Pharmaceuticals) is .
-
What is GTx (Pharmaceuticals)’s current revenue?
The current revenue for GTx (Pharmaceuticals) is .
-
How much funding has GTx (Pharmaceuticals) raised over time?
GTx (Pharmaceuticals) has raised $190M.
-
Who are GTx (Pharmaceuticals)’s investors?
Aisling Capital, Amzak Capital Management, BVF Partners, MB Venture Partners, and Oracle Investment Management are 5 of 7 investors who have invested in GTx (Pharmaceuticals).
-
Who are GTx (Pharmaceuticals)’s competitors?
Sarepta Therapeutics, Pliant Therapeutics, Exelixis, Kyntra Bio, and Monopar Therapeutics are some of the 40 competitors of GTx (Pharmaceuticals).
-
When was GTx (Pharmaceuticals) acquired?
GTx (Pharmaceuticals) was acquired on 07-Jun-2019.
-
Who acquired GTx (Pharmaceuticals)?
GTx (Pharmaceuticals) was acquired by Oncternal Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process